tiprankstipranks
Trending News
More News >
Colan Totte.Co.,Ltd. (JP:7792)
:7792
Japanese Market
Advertisement

Colan Totte.Co.,Ltd. (7792) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7792

Colan Totte.Co.,Ltd.

(7792)

Select Model
Select Model
Select Model
Outperform 77 (OpenAI - 4o)
Rating:77Outperform
Price Target:
¥1,570.00
▲(1.95% Upside)
Colan Totte.Co.,Ltd. receives a strong overall score driven by robust financial performance and attractive valuation. The technical analysis supports a bullish outlook, though some caution is warranted due to the RSI indicating potential overbought conditions.

Colan Totte.Co.,Ltd. (7792) vs. iShares MSCI Japan ETF (EWJ)

Colan Totte.Co.,Ltd. Business Overview & Revenue Model

Company DescriptionColan Totte.Co.,Ltd. develops and sells therapy devices under the Colantotte brand in Japan and internationally. The company offers household magnetic therapy devices, such as magnetic necklaces for the neck and shoulders, loop series for the arms, supporters, recovery wear, and magnetic pillows, as well as sleep supplements. It also operates the Colantotte Safety System, an emergency contact service through an emergency contact card, pendant, or keychain. The company sells its products through wholesale, directly managed shops, and online. The company was incorporated in 1997 and is based in Osaka, Japan.
How the Company Makes MoneyColan Totte Co., Ltd. generates revenue through the sale of its health and wellness products, primarily focusing on magnetic therapy devices. The company markets its products through various distribution channels, including retail stores, online platforms, and direct sales. Key revenue streams include direct consumer sales and partnerships with retailers and distributors who carry their products. Significant factors contributing to its earnings include its strong brand reputation, innovation in product design, and a growing global demand for alternative and complementary health therapies.

Colan Totte.Co.,Ltd. Financial Statement Overview

Summary
Colan Totte.Co.,Ltd. demonstrates a strong financial position with significant revenue growth, high profitability margins, and stable balance sheet metrics. However, fluctuations in cash flow metrics introduce some uncertainty.
Income Statement
85
Very Positive
Colan Totte.Co.,Ltd. shows strong financial performance with robust revenue growth and improving profitability. The TTM (Trailing-Twelve-Months) revenue growth rate is impressive, indicating a positive trajectory. The gross profit margin and net profit margin are healthy, showcasing efficient cost management and operational success. Both EBIT and EBITDA margins are strong, reinforcing the company's profitability.
Balance Sheet
78
Positive
The balance sheet reflects solid financial stability with a low debt-to-equity ratio, suggesting prudent leverage management. The company has a high equity ratio, indicating a strong capital structure with significant shareholder investment. Return on Equity (ROE) is commendable, highlighting effective utilization of equity in generating profits.
Cash Flow
65
Positive
While the operating cash flow is substantial, the free cash flow growth has fluctuated, reflecting potential volatility in capital expenditures. The operating cash flow to net income ratio suggests that cash generation is in line with profitability. However, the absence of recent free cash flow data in TTM limits the analysis of cash flow resilience.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.28B5.94B5.41B4.66B3.71B2.89B
Gross Profit4.21B3.97B3.45B3.04B2.46B1.82B
EBITDA1.78B1.57B1.10B1.02B691.13M566.85M
Net Income1.26B1.02B645.02M610.45M420.50M324.81M
Balance Sheet
Total Assets6.00B5.43B4.88B4.10B3.62B2.32B
Cash, Cash Equivalents and Short-Term Investments2.00B1.76B1.79B1.34B1.55B507.34M
Total Debt5.34M8.69M1.27M270.48M439.84M912.09M
Total Liabilities1.41B1.32B1.61B1.36B1.38B1.44B
Stockholders Equity4.58B4.11B3.27B2.75B2.24B886.03M
Cash Flow
Free Cash Flow0.00357.26M867.34M75.48M597.37M317.68M
Operating Cash Flow0.00883.77M955.70M148.09M637.27M378.76M
Investing Cash Flow0.00-736.91M-83.80M-80.38M-51.45M-59.48M
Financing Cash Flow0.00-180.15M-410.10M-274.23M452.40M-236.52M

Colan Totte.Co.,Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1540.00
Price Trends
50DMA
1468.58
Positive
100DMA
1387.63
Positive
200DMA
1232.73
Positive
Market Momentum
MACD
21.95
Negative
RSI
67.55
Neutral
STOCH
84.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7792, the sentiment is Positive. The current price of 1540 is above the 20-day moving average (MA) of 1483.00, above the 50-day MA of 1468.58, and above the 200-day MA of 1232.73, indicating a bullish trend. The MACD of 21.95 indicates Negative momentum. The RSI at 67.55 is Neutral, neither overbought nor oversold. The STOCH value of 84.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7792.

Colan Totte.Co.,Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
9.12B12.225.34%3.69%3.38%88.65%
77
Outperform
¥13.98B11.15
1.95%12.36%38.55%
75
Outperform
8.95B11.585.54%1.92%9.07%43.42%
74
Outperform
17.43B16.720.00%3.33%-8.07%-38.21%
69
Neutral
32.86B10.759.10%2.44%7.99%28.81%
56
Neutral
13.25B-19.79-1.87%2.98%4.84%-148.94%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7792
Colan Totte.Co.,Ltd.
1,540.00
468.95
43.78%
JP:5187
Create Medic Co., Ltd.
1,003.00
80.08
8.68%
JP:6678
Techno Medica Co., Ltd.
2,045.00
100.10
5.15%
JP:6823
Rion Co., Ltd.
2,665.00
616.70
30.11%
JP:7600
Japan Medical Dynamic Marketing, Inc.
503.00
-202.24
-28.68%
JP:7963
Koken Ltd.
1,820.00
293.36
19.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 10, 2025